Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson’s disease: systematic review, meta-analysis, and economic evaluation

AIMS: To review the evidence for efficacy, safety, and cost-effectiveness of levodopa/carbidopa/entacapone (LCE) compared with levodopa/dopa-decarboxyiase inhibitor (DDCI) for Parkinson’s disease (PD). METHODS: PubMed, Embase, the Cochrane Library, and Chinese databases WangFang Data, Chinese Sci-te...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Zhan-Miao, Qiu, Ting-Ting, Zhang, Yuan, Liu, Na, Zhai, Suo-Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907888/
https://www.ncbi.nlm.nih.gov/pubmed/29713179
http://dx.doi.org/10.2147/TCRM.S163190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907888/
https://www.ncbi.nlm.nih.gov/pubmed/29713179
http://dx.doi.org/10.2147/TCRM.S163190

Ejemplares similares